ListarINIBIC-OCT - Artigos por tema "Safety"

Mostrando ítems 1-2 de 2

    • A new scenario in metastatic renal cell carcinoma: a SOG‑GU consensus 

      Vázquez Estévez, Sergio; Anido Herranz, Urbano; Lázaro Quintela, Martín; Fernández Calvo, Ovidio; Fernández-Núñez, Natalia; Dios Álvarez, N. de; Varela, V.; Campos Balea, B.; Agraso, S.; Areses, M. C.; Iglesias, L.; Blanco, Moisés; Maciá, S.; Antón-Aparicio, Luis M. (Springer, 2020-02-15)
      [Abstract] Background This article describes and compares approved targeted therapies and the newer immunotherapy agents. Materials and methods This article especially performs an in-depth review of currently available ...

    • Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies 

      Castellano, Daniel; Maroto, José Pablo; Espinosa, Enrique; Grande, Enrique; Bolós Fernández, Victoria; Llinares, Julia; Esteban, Emilio; González del Alba, Aránzazu; Climent, Miguel Ángel; Arranz, José Ángel; Méndez, María José; Fernández Parra, Eva; Antón-Aparicio, Luis M.; Bayona, Cristina; Gallegos, Isabel; Gallardo, Enrique; Samaniego, Luz; García Donas, Jesús (Taylor & Francis, 2017-08-28)
      [Abstract] Background: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. Objective: To evaluate ...